Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Cilengitide may stop the growth of glioblastoma multiforme by blocking blood flow to the
tumor. Giving cilengitide before and after surgery may be an effective treatment for
glioblastoma multiforme. This phase II trial is studying how well cilengitide works in
treating patients who are undergoing surgery for recurrent or progressive glioblastoma
multiforme.